A 2025 systematic review by Vasireddi and colleagues in HSS Journal screened 544 published papers and identified 36 meeting inclusion criteria 35 preclinical studies and only one human study: an uncontrolled, unblinded, retrospective case series of 12 patients receiving intra-articular BPC-157 for chronic knee pain, in which 7 of 12 (58%) reported self-described relief lasting more than 6 months, with no dose, effect size, or systematically collected adverse events published
A recent study conducted on a relatively small cohort (43 enrolled patients) indicated that nebivolol may improve insulin sensitivity and glucose utilization, potentially leading to better glycemic control in patients with diabetes mellitus or cardiometabolic syndrome
Book a consultation today to learn how to support your body while on GLP-1 treatment.
Ubiquitin-proteasome system and mitochondria - reciprocity
Always follow the dose, schedule, and injection technique your licensed clinician prescribed